brokers bullish on bioscience

Today's snippet from a well-connected organisation dealing in Aussie biotechs.


I believe we have all the hallmarks of a supercycle starting in Australia in life sciences. It is so similar to commodities, where years of underinvestment in R&D by big Pharma (in commodities it was exploration) has led to a genuine lack of new blockbuster drug supply, right as big Pharma faces the patent cliff. This is leading to big Pharma attempting to commercialise/accelerate development of next generation drugs/devices, many of which are patented by Australian listed companies. You will see more M&As and JVs in the Australian life sciences sector, which both reduces the requirement for equity capital from the sector and validates the science.